Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60  years: A double-blind, non-inferiority, randomized controlled trial

CONCLUSION: Our findings support the non-inferiority of the FluGuard vaccine to the Vaxigrip vaccine regarding immunogenicity and safety.CLINICAL TRIAL REGISTRY: The study protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210901052358N5).PMID:38423811 | DOI:10.1016/j.vaccine.2024.02.073

Source: Vaccine - February 29, 2024 Category: Allergy & Immunology Authors: Davood Yadegarynia Amirreza Keyvanfar Hossein Keyvani Shabnam Tehrani Shahnaz Sali Sara Abolghasemi Source Type: research